| http://www.w3.org/ns/prov#value | - cruiting patients with several types of cancer, whilst the Phase II portion is limited to patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer [76].Another active small-molecule Hsp90 inhibitor based on the 6,7-dihydroindazol-4-one scaffold is SNX-5422 [77].
|
